NASDAQ:SRPT实时 99.98-3.34-3.24%2025-03-10 16:00:00 今开:101.84 昨收:103.03 今日区间:98.82-102.14 52周区间:78.67-173.25 成交量:163.92万 成交额:16380.93万 市值:96.88亿 市盈率:77.35 贝塔系数: 每股收益:1.2926 盘后99.980.290.29%成交量30.28万2025-03-10 18:29...
View the most recent data and latest information on option chains for Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) at Nasdaq.com.
really tight guidance. So, I almost feel like you have to start forms that will track all the way out through some element of 2025. Can you talk to the volume of start forms and what the levers are for the top and the bottom and ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 E
The requests Sarepta Therapeutics (NASDAQ:SRPT) has gotten from the FDA represent a sign of FDA seriousness towards bringing the firm’s drug eteplirsen for...
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) --Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that were previously approved by the Compensation Committee of its Board of ...
Trending Tickers Above average volume. SRPT $78.33 -22.71% -23.02 NIU $3.91 11.25% 0.40 MUFG $14.29 3.10% 0.43 HUYA $3.72 -18.06% -0.82 Access Premium Tools Search Clear Search Advanced Search Search Results Symbols Loading... Private Companies Loading... Recently Viewed Tickers All...
Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), MannKind (MNKD) Feb. 27, 2025 at 7:10 a.m. ETon TipRanks.com Wells Fargo Sticks to Its Buy Rating for MannKind (MNKD) Feb. 27, 2025 at 6:37 a.m. ETon TipRanks.com ...
Create a free account to read the full article Gain access to the world’s leading investment community. Already registered? Sign in Create Free Account By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy or Continue with Google Continue ...
Roche has a collaboration agreement withSarepta TherapeuticsSRPTfor Elevidys, whereby it is responsible to commercialize Elevidys outside the United States. Last week, Sarepta announced that the FDA has converted the accelerated approval granted to Elevidys to a traditional approval and expanded the...